Axsome Therapeutics stock
AXSMNASDAQAxsome Therapeutics, Inc., HealthcareISIN US05464T1043
32Score 32 out of 100, Weak
Price and trend
39 / 100
Price history
+6.9% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 42% below its 52-week high. Largest decline in 11 years: 87% (January 2016 to December 2018).
Chart figures for advanced users
- SMA 50$174.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$197.47
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$129.80
- The lowest closing price of the last twelve months.
- Resistance$255.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Axsome Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $7.85B, is number 52 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $638.5M (up 65.5% year on year) and a loss of $183.17M.
- For fiscal 2026, analysts expect on average revenue of $951.04M (up 49%) and adjusted earnings per share of −$2.62.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 669 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $313.86M, financial debt $218.67M.
Weaknesses
- DilutionShare count up 34% since 2020.Capital allocation 18
- Loss-makingLoss of $157.29M over the last 12 months.Fundamentals 17
- High debtDebt 2.07 times equity (latest quarter), Biotechnology median 0.09.Stability 36
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 30 to 32.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 54.2% on the twelve months before. Revenue turned from negative at the start of the period to positive ($638.5M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating −27%, net −29%. Last 12 months: net −18%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 2 Nov 2026EPS reported −$0.25 (expected −$0.63)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 16.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.62+5.8%
- Revenue
- $951.04M−0.7%
- Earnings per share
- $3.54−16.9%
- Revenue
- $1.46B−3.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.4%No numerical guidance; continued growth across the product portfolio is expected, with better guidance only towards year end.
“Underlying demand growth for SYMBRAVO is also accelerating, and we expect SUNOSI growth to continue outpacing the market, positioning us for continued strong growth across the entire commercial portfolio.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $48.92M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Jacobson Mark L.Sale
3 Sept 2026, Chief Operating Officer
- Shares
- 10,000
- Price
- $208.65
- Value
- $2.09M
- Tabuteau HerriotSale
6 Aug 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 4,660
- Price
- $213.95
- Value
- $997,007
- Tabuteau HerriotSale
5 Aug 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 45,004
- Price
- $212.01
- Value
- $9.54M
Show 11 more
- Tabuteau HerriotSale
1 Jul 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 49,666
- Price
- $240.25
- Value
- $11.93M
- Jeffs RogerSale
11 Jun 2026, Board
- Shares
- 286
- Price
- $249.12
- Value
- $71,248
- Jeffs RogerSale
10 Jun 2026, Board
- Shares
- 286
- Price
- $246.18
- Value
- $70,407
- Mahony SusanSale
10 Jun 2026, Board
- Shares
- 300
- Price
- $246.18
- Value
- $73,854
- Coleman MarkSale
10 Jun 2026, Board
- Shares
- 643
- Price
- $249.00
- Value
- $160,107
- Mahony SusanSale
9 Jun 2026, Board
- Shares
- 300
- Price
- $237.21
- Value
- $71,163
- Tabuteau HerriotSale
9 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 49,670
- Price
- $241.01
- Value
- $11.97M
- Pizzie NickSale
9 Jun 2026, Chief Financial Officer
- Shares
- 33,000
- Price
- $240.09
- Value
- $7.92M
- Coleman MarkSale
2 Jun 2026, Board
- Shares
- 5,537
- Price
- $223.39
- Value
- $1.24M
- Coleman MarkSale
1 Jun 2026, Board
- Shares
- 6,000
- Price
- $230.30
- Value
- $1.38M
- Coleman MarkSale
29 May 2026, Board
- Shares
- 6,000
- Price
- $233.46
- Value
- $1.4M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Axsome Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CytokineticsCYTK $8.15B34
- 10x GenomicsTXG $8.12B43
- AbivaxABVX.PA $8.11B36
- Twist BioscienceTWST $8.07B45
- Rhythm PharmaceuticalsRYTM $7.78B46
- ImmunovantIMVT $7.64B45
- Bachem HoldingBANB.SW $7.3B58
- ImmunityBioIBRX $7.1B38
ETFs that hold Axsome Therapeutics
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 0.94% | 0.89% | €11.61M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.51% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.45% | 0.35% | €1.21B |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.27% | 0.40% | €807M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.09% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.02% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.